Pfizer (PFE): insider & executive buying
Pfizer · Health Care · ref. ETF XLV · price $28.02
In short — 3 insiders bought Pfizer over ~6 months (3 buys, total $3.0M, latest Aug 12, 26) — cluster buy. Public Form 4 data, informative (not a performance signal).
Are Pfizer's executives buying their own shares? Here are the disclosed insider buys over the last 6 months — a transparency data point, not an outperformance signal.
📈 1-year price
$28.02+13.9% over range
Aug 28, 25low $23.6 · high $28.57Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 12 analysts
Latest insider buys on Pfizer
| Date | Insider | Role | Shares | Amount |
|---|---|---|---|---|
| Aug 12, 26 | Bourla Albert | COB, CEO | 38,000 | $1.0M |
| Aug 5, 26 | Blaylock Ronald E | Dir | 39,231 | $999k |
| Aug 5, 26 | Buckley Mortimer J | Dir | 37,632 | $960k |
⚠️ Open-market buys reported to the SEC (Form 4). Transparency data, not advice nor an outperformance signal (our backtests show no reliable edge).
Frequently asked questions
Have Pfizer's executives bought shares recently?
3 Pfizer insider(s) bought $3.0M over ~6 months (latest Aug 12, 26). A buy shows confidence, but our backtests show no performance edge.
Is insider buying a good signal for PFE?
It's useful transparency data, but NOT a performance guarantee: our historical tests show no reliable edge from following insider buys. Cross-check with fundamentals and analyst views.
Where does this data come from?
From Form 4 filings with the SEC (mandatory for officers and 10%+ holders), aggregated and refreshed regularly.
💬 A question about Pfizer? The JPI assistant answers using our backtest data.